Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: ACAN who wrote (22627)	2/8/2007 3:55:17 PM
From: Galirayo	Respond to of 23958

So, it's no surprise that I follow developments at Northfield Laboratories (NFLD - commentary - Cramer's Take) with great interest. Last month, the company's stock cratered after results from a pivotal phase III study revealed that trauma patients given its blood substitute Polyheme had a higher death rate than patients given a combination of saline and donated blood. Needless to say, these were not the results that Northfield management and its supporters were hoping for. The $14 stock fell to the $4 level on the announcement. (Short-sellers, obviously, were a bit more jubilant.) End of story, right? Not a chance. Northfield is forging ahead with plans to seek Food and Drug Administration approval for Polyheme later this year. On the company's quarterly conference call with investors Wednesday, CEO Steven Gould said the company was actually encouraged by the Polyheme data and is optimistic about its chances of success at the FDA. thestreet.com +++++++++++++++++++++++++ I want some of that Blood ???